Cargando…

Attenuation of a recombinant Marek's disease virus lacking the meq oncogene and evaluation on its immune efficacy against Marek's disease virus

SC9-2 is a recombinant Marek's disease virus (MDV) strain lacking the meq oncogene. Previous study demonstrated that SC9-2 virus provides good protection against challenge with a very virulent MDV rMd5, but it induces immunosuppressive effects in specific pathogen-free (SPF) chickens. In the pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Peng, Cui, Ning, Liu, Linqing, Su, Shuai, Cheng, Ziqiang, Chen, Ruiai, Li, Yanpeng, Cui, Zhizhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7587640/
https://www.ncbi.nlm.nih.gov/pubmed/32241474
http://dx.doi.org/10.1016/j.psj.2019.11.059
_version_ 1783600216527601664
author Sun, Peng
Cui, Ning
Liu, Linqing
Su, Shuai
Cheng, Ziqiang
Chen, Ruiai
Li, Yanpeng
Cui, Zhizhong
author_facet Sun, Peng
Cui, Ning
Liu, Linqing
Su, Shuai
Cheng, Ziqiang
Chen, Ruiai
Li, Yanpeng
Cui, Zhizhong
author_sort Sun, Peng
collection PubMed
description SC9-2 is a recombinant Marek's disease virus (MDV) strain lacking the meq oncogene. Previous study demonstrated that SC9-2 virus provides good protection against challenge with a very virulent MDV rMd5, but it induces immunosuppressive effects in specific pathogen-free (SPF) chickens. In the present study, SC9-2 was serially passaged on chicken embryo fibroblast (CEF) cell cultures. The pathogenicity and immune efficacy of SC9-2/10(th) and SC9-2/40(th) against rMd5 were evaluated. Animal experimental results showed that SC9-2/10(th) and SC9-2/40(th) showed no lethality or tumorigenicity in SPF chickens. Body weight of chickens inoculated with SC9-2/40(th) were significantly higher than that of the chickens inoculated with SC9-2/10(th) but lower than that of the uninoculated controls. The severity of bursa and thymus atrophy (BTA) and spleen enlargement in SC9-2/40(th)-inoculated chickens were also weaker than the SC9-2/10(th)-inoculated ones but stronger than the uninoculated controls. Chickens inoculated with SC9-2/40(th) and SC9-2/10(th) showed similar antibody levels induced by H9N2 subtype avian influenza virus/Newcastle disease virus inactivated vaccines, both of which were lower than the uninoculated controls. Replication of SC9-2/40(th) was significantly lower than SC9-2/10(th) in feather follicle epithelium (FFE) of infected chickens. The immune protection index of SC9-2/40(th) was also lower than that of SC9-2/10(th), but the difference was not significantly, and both of which were significant higher than that of the commercial MDV vaccine CVI988/Rispens. The results of our studies demonstrated that SC9-2/40(th) showed weaker severity of BTA, spleen enlargement, and body weight loss and lower replication level in FFE than SC9-2/10(th) in SPF chickens. However, SC9-2/40(th) was able to confer better immune protection as compared with CVI988/Rispens vaccination in SPF chickens. In conclusion, serially attenuation of SC9-2 in CEFs reduced the lymphoid organ atrophy and replication in SPF chickens, and the immune protective efficacy of attenuated viruses was still superior than CVI988/Rispens.
format Online
Article
Text
id pubmed-7587640
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-75876402020-10-27 Attenuation of a recombinant Marek's disease virus lacking the meq oncogene and evaluation on its immune efficacy against Marek's disease virus Sun, Peng Cui, Ning Liu, Linqing Su, Shuai Cheng, Ziqiang Chen, Ruiai Li, Yanpeng Cui, Zhizhong Poult Sci Immunology, Health and Disease SC9-2 is a recombinant Marek's disease virus (MDV) strain lacking the meq oncogene. Previous study demonstrated that SC9-2 virus provides good protection against challenge with a very virulent MDV rMd5, but it induces immunosuppressive effects in specific pathogen-free (SPF) chickens. In the present study, SC9-2 was serially passaged on chicken embryo fibroblast (CEF) cell cultures. The pathogenicity and immune efficacy of SC9-2/10(th) and SC9-2/40(th) against rMd5 were evaluated. Animal experimental results showed that SC9-2/10(th) and SC9-2/40(th) showed no lethality or tumorigenicity in SPF chickens. Body weight of chickens inoculated with SC9-2/40(th) were significantly higher than that of the chickens inoculated with SC9-2/10(th) but lower than that of the uninoculated controls. The severity of bursa and thymus atrophy (BTA) and spleen enlargement in SC9-2/40(th)-inoculated chickens were also weaker than the SC9-2/10(th)-inoculated ones but stronger than the uninoculated controls. Chickens inoculated with SC9-2/40(th) and SC9-2/10(th) showed similar antibody levels induced by H9N2 subtype avian influenza virus/Newcastle disease virus inactivated vaccines, both of which were lower than the uninoculated controls. Replication of SC9-2/40(th) was significantly lower than SC9-2/10(th) in feather follicle epithelium (FFE) of infected chickens. The immune protection index of SC9-2/40(th) was also lower than that of SC9-2/10(th), but the difference was not significantly, and both of which were significant higher than that of the commercial MDV vaccine CVI988/Rispens. The results of our studies demonstrated that SC9-2/40(th) showed weaker severity of BTA, spleen enlargement, and body weight loss and lower replication level in FFE than SC9-2/10(th) in SPF chickens. However, SC9-2/40(th) was able to confer better immune protection as compared with CVI988/Rispens vaccination in SPF chickens. In conclusion, serially attenuation of SC9-2 in CEFs reduced the lymphoid organ atrophy and replication in SPF chickens, and the immune protective efficacy of attenuated viruses was still superior than CVI988/Rispens. Elsevier 2020-01-22 /pmc/articles/PMC7587640/ /pubmed/32241474 http://dx.doi.org/10.1016/j.psj.2019.11.059 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Immunology, Health and Disease
Sun, Peng
Cui, Ning
Liu, Linqing
Su, Shuai
Cheng, Ziqiang
Chen, Ruiai
Li, Yanpeng
Cui, Zhizhong
Attenuation of a recombinant Marek's disease virus lacking the meq oncogene and evaluation on its immune efficacy against Marek's disease virus
title Attenuation of a recombinant Marek's disease virus lacking the meq oncogene and evaluation on its immune efficacy against Marek's disease virus
title_full Attenuation of a recombinant Marek's disease virus lacking the meq oncogene and evaluation on its immune efficacy against Marek's disease virus
title_fullStr Attenuation of a recombinant Marek's disease virus lacking the meq oncogene and evaluation on its immune efficacy against Marek's disease virus
title_full_unstemmed Attenuation of a recombinant Marek's disease virus lacking the meq oncogene and evaluation on its immune efficacy against Marek's disease virus
title_short Attenuation of a recombinant Marek's disease virus lacking the meq oncogene and evaluation on its immune efficacy against Marek's disease virus
title_sort attenuation of a recombinant marek's disease virus lacking the meq oncogene and evaluation on its immune efficacy against marek's disease virus
topic Immunology, Health and Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7587640/
https://www.ncbi.nlm.nih.gov/pubmed/32241474
http://dx.doi.org/10.1016/j.psj.2019.11.059
work_keys_str_mv AT sunpeng attenuationofarecombinantmareksdiseaseviruslackingthemeqoncogeneandevaluationonitsimmuneefficacyagainstmareksdiseasevirus
AT cuining attenuationofarecombinantmareksdiseaseviruslackingthemeqoncogeneandevaluationonitsimmuneefficacyagainstmareksdiseasevirus
AT liulinqing attenuationofarecombinantmareksdiseaseviruslackingthemeqoncogeneandevaluationonitsimmuneefficacyagainstmareksdiseasevirus
AT sushuai attenuationofarecombinantmareksdiseaseviruslackingthemeqoncogeneandevaluationonitsimmuneefficacyagainstmareksdiseasevirus
AT chengziqiang attenuationofarecombinantmareksdiseaseviruslackingthemeqoncogeneandevaluationonitsimmuneefficacyagainstmareksdiseasevirus
AT chenruiai attenuationofarecombinantmareksdiseaseviruslackingthemeqoncogeneandevaluationonitsimmuneefficacyagainstmareksdiseasevirus
AT liyanpeng attenuationofarecombinantmareksdiseaseviruslackingthemeqoncogeneandevaluationonitsimmuneefficacyagainstmareksdiseasevirus
AT cuizhizhong attenuationofarecombinantmareksdiseaseviruslackingthemeqoncogeneandevaluationonitsimmuneefficacyagainstmareksdiseasevirus